GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (LTS:0NZT) » Definitions » Short Percentage of Float

UCB (LTS:0NZT) Short Percentage of Float


View and export this data going back to 2009. Start your Free Trial

What is UCB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of UCB's Short Percentage of Float

For the Biotechnology subindustry, UCB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UCB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where UCB's Short Percentage of Float falls into.


UCB (LTS:0NZT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (LTS:0NZT) » Definitions » Short Percentage of Float
Comparable Companies
XBRU:ARGX XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 BNTX OCSE:GMAB ALNY BGNE BMRN
Traded in Other Exchanges
UCBJY:USA UCBJF:USA UCBb:UK UNC:Germany UCB:Belgium UCB:Austria
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
Website
https://www.ucb.com
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (LTS:0NZT) Headlines

No Headlines